TED Ted Baker Plc

Company Strategy Briefing, March 22nd 2005 1 March 2005 Tepnel Life Sciences PLC COMPANY STRATEGY Briefing, March 22nd2005 Advance notice of Preliminary Results Manchester, UK. 1 March 2005� The Board of Tepnel Life Sciences' (AIM: TED) are pleased to invite investors to their Company Strategy Briefing to be held on 22nd March 2005 from 11am - 12:30pm. Venue: New Connaught Rooms, Covent Garden Exhibition Centre, 61-65 Great Queen Street, London, WC2B 5DA During this briefing the Company will present its preliminary results for year ended 31 December 2004 together with a presentation on strategy and direction for the future. Any investor who would like to attend should contact: Elni Stofberg, De Facto Communications (tel: +44 (0)207 940 1022), e-mail: e.stofberg@defacto.com -ends- For Further Information: Tepnel Life Sciences plc Ben Matzilevich, CEO Gron Ffoulkes-Davies, Finance Director 0161 946 2200 Seymour Pierce Mark Percy, Corporate Finance 0207 107 8000 De Facto Communications Richard Anderson 020 7940 1000 Notes to Editors About Tepnel Life Sciences plc Tepnel is a UK-based international life sciences instrumentation and services company with a `tri-polar' strategy focused on providing the biomedical industry with high-throughput automated DNA purification systems, manual DNA purification kits and reagents, as well as scientific services for nucleic acid purification, drug analysis, genotyping and genetically modified foods. Tepnel was founded in 1992 to exploit DNA technology generated at UMIST (University of Manchester Institute of Science and Technology) and is quoted on the AIM segment of the London Stock Exchange (AIM: TED). More information on Tepnel can be found at www.tepnel.com. END

Copyright